ALNY Alnylam Pharmaceuticals Inc.

119.53
-1.08  -1%
Previous Close 120.61
Open 120.5
Price To Book 8.29
Market Cap 13,326,369,100
Shares 111,489,744
Volume 114,667
Short Ratio
Av. Daily Volume 731,393
Stock charts supplied by TradingView

NewsSee all news

  1. Alnylam to Webcast Presentations at Upcoming December Investor Conferences

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2nd Annual HealthCONx

  2. Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day

    − Expects to Exceed Alnylam 2020 Goals with Four Marketed Products, 14 Organic Clinical Stage Programs, Including 6 in Late-Stage Development, Across 4 Strategic Therapeutic Areas (STArs), by End of 2020 – – Initiates

  3. Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)

    − Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial

  4. Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

    − GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA

  5. Alnylam Announces Second Annual Advocacy for Impact Grants Program

    − Program Aims to Inspire Creative Patient Advocacy Solutions to Unique Challenges in Rare Disease Communities − − Funding Will Support Unmet Needs in the ATTR Amyloidosis, Acute Hepatic Porphyria and Primary

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced November 20, 2019.
Givosiran
Acute hepatic porphyrias
Phase 3 data met all endpoints - September 25, 2019. Data November 18, 2019 noted LDL-C reductions of 50%.
Inclisiran - ORION-9
Hypercholesterolemia
Phase 1/2 additional data due 1H 2020.
ALN-HBV02 (VIR-2218)
Chronic hepatitis B virus (HBV)
Phase 3 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-A
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial ongoing.
ALN-CC5 (cemdisiran)
IgA nephropathy
Phase 3 ongoing.
Fitusiran (ATLAS)
Hemophilia
Phase 3 trial enrolling - noted December 6, 2018.
ALN-TTRsc02 - HELIOS-A
ATTR amyloidosis
Phase 3 data met all endpoints - September 25, 2019. Detailed data due at AHA noted 58% LDL-C lowering.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 data due late-2019.
ALN-AAT02
alpha-1 anti-trypsin deficiency-associated liver disease
Phase 3 top-line data due mid-2020.
Lumasiran (ALN-GO1) ILLUMINATE-B
Primary Hyperoxaluria Type 1
Phase 3 enrolment to be completed late-2020.
Patisiran APOLLO-B
Wild-type ATTR amyloidosis patients with cardiomyopathy
Phase 3 trial data due end of 2020.
Lumasiran (ALN-GO1) ILLUMINATE-C
Impaired renal function
Phase 1 trial ongoing.
ALN-AGT
Hypertension
Phase 3 trial has been initiated - noted November 22, 2019.
ALN-TTRsc02 (vutrisiran) - HELIOS-B
ATTR amyloidosis with cardiomyopathy

Latest News

  1. Alnylam to Webcast Presentations at Upcoming December Investor Conferences

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2nd Annual HealthCONx

  2. Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day

    − Expects to Exceed Alnylam 2020 Goals with Four Marketed Products, 14 Organic Clinical Stage Programs, Including 6 in Late-Stage Development, Across 4 Strategic Therapeutic Areas (STArs), by End of 2020 – – Initiates

  3. Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)

    − Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial

  4. Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

    − GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA

  5. Alnylam Announces Second Annual Advocacy for Impact Grants Program

    − Program Aims to Inspire Creative Patient Advocacy Solutions to Unique Challenges in Rare Disease Communities − − Funding Will Support Unmet Needs in the ATTR Amyloidosis, Acute Hepatic Porphyria and Primary

  6. Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019

  7. Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

    − Initial Results From ILLUMINATE-C Expected in Late 2020 – − In Phase 2 OLE, Lumasiran Treatment Resulted in 76 percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline – Alnylam

  8. Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity

    − Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Worldwide – − Initiated APOLLO-B Phase 3 Study of

  9. Alnylam Named #1 Biopharma Employer by Science Magazine

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that Science magazine has named the company the world's number one employer in its annual survey of the biotech and

  10. Alnylam's Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation Chemistry at Alnylam, has been awarded

  11. Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

    – Filing Marks the First RNAi Therapeutic to be Submitted for Potential Approval in Latin America – – Submission Made Under the Accelerated Regulatory Pathway for Rare Diseases – Alnylam Pharmaceuticals, Inc.

  12. Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,

  13. Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

    – APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated

  14. Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on

  15. 1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day

    − Alnylam Supports Nearly 40 Organizations in Greater Boston, Philadelphia, Europe and Brazil in "Helping Hands" Community Service Day – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics

  16. Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias

    − Porphyria Attack Reductions Observed in ENVISION Phase 3 Study Maintained with Ongoing Givosiran Dosing in Open-Label Extension (OLE) Study – − In ENVISION Phase 3 Study, Patients Receiving Givosiran Reported

  17. Alnylam to Host Sixth Annual "RNAi Roundtable" Webcast Series

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to kick off its 6th annual series of "RNAi Roundtable" webcasts over the coming weeks. The series will

  18. Yumanity Therapeutics Appoints Patricia Allen to its Board of Directors

    Ms. Allen Brings Over 25 Years of Financial Leadership Experience to the Company Yumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases,

  19. Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients

    − Neurofilament Light Chain (NfL) Identified as a Potential Biomarker of Nerve Damage and Polyneuropathy due to hATTR Amyloidosis; ONPATTRO® (patisiran) Treatment Found to Reduce NfL Levels Relative to Placebo in APOLLO

  20. Alnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in

  21. Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17th Annual Morgan Stanley Global Healthcare Conference on